Phase-III Ophthalmic Study is Approved within 44 Working Days
The end of the year was marked for GCT team with yet another achievement. Clinical trial approval was received ahead of official timelines for Phase III study, – the whole review process, including Q/A with competent authority, lasted 44 working days.
A multi-centre, randomized, investigator-masked study is designed to evaluate the investigational drug in patients with ocular hypertension or primary open angle glaucoma – conditions in which the measured eye pressure is consistently greater than normal.
GCT team’s proactive approach during the submission and the review stages led to this rapid result.
Updated: January 10, 2019